10/19/2017
This week, 20/20 GeneSystems launched our first equity crowdfunding campaign. Please visit Microventures Crowdfunding today and consider making an investment yourself and sharing the link with your friends and colleagues, even those positioned to make only modest investments. (Either accredited or non-accredited investors may participate with a minimum investment of only $101.) In addition to obtaining our stock, investors receive complimentary, early access to our new OneTest, the first blood test for screening multiple cancers powered by a big data approach coupled with machine learning algorithms.
Why Crowdfunding ? Why Now ?
Until last year, companies like 20/20 could raise most of its needed funds only from professional money managers or high-net worth individuals, effectively excluding more than 98% of the adult population. With the recent implementation of the JOBS Act by the SEC, nearly everyone can for the first time invest in privately held emerging growth companies like ours.
Crowdfunding is much more than a financing tool--it provides marketplace validation of consumer demand for products before they launch. With the anticipated introduction of OneTest early in 2018 the time was right to engage with the consumers interested in this potentially ground breaking product for preventing lethal cancers.
Success with the type of smaller equity crowdfunding campaign we initiated this week under Reg. CF can pave the way for a much larger equity crowdfunding approach under Reg. A+, sometimes referred to as a "mini IPO" where companies can list on national stock exchanges such as NYSE or NASDAQ.
concept dollar get more and more valuable isolated on white
The crowd provides validation of market demand for products in additional to capital
Kindly share the link to Microventures Crowdfunding with your social media friends and consider making an investment yourself. Thanks in advance for your support!
https://app.microventures.com/crowdfunding/2020-genesystems
